Literature DB >> 30218547

Attenuation of murine allergic airway inflammation with a CXCR1/CXCR2 chemokine receptor inhibitor.

Koa Hosoki1, Krishna Rajarathnam2, Sanjiv Sur1,3.   

Abstract

Entities:  

Year:  2018        PMID： 30218547      PMCID： PMC6660919          DOI： 10.1111/cea.13275

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN： 0954-7894            Impact factor:   5.018


× No keyword cloud information.
  10 in total

1.  Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.

Authors:  Mohd W Nasser; Sandeep K Raghuwanshi; Delores J Grant; Venkatakrishna R Jala; Krishna Rajarathnam; Ricardo M Richardson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

2.  CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.

Authors:  Antonio Citro; Elisa Cantarelli; Paola Maffi; Rita Nano; Raffaella Melzi; Alessia Mercalli; Erica Dugnani; Valeria Sordi; Paola Magistretti; Luisa Daffonchio; Pier Adelchi Ruffini; Marcello Allegretti; Antonio Secchi; Ezio Bonifacio; Lorenzo Piemonti
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

3.  Mouse and human neutrophils induce anaphylaxis.

Authors:  Friederike Jönsson; David A Mancardi; Yoshihiro Kita; Hajime Karasuyama; Bruno Iannascoli; Nico Van Rooijen; Takao Shimizu; Marc Daëron; Pierre Bruhns
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

4.  Facilitation of Allergic Sensitization and Allergic Airway Inflammation by Pollen-Induced Innate Neutrophil Recruitment.

Authors:  Koa Hosoki; Leopoldo Aguilera-Aguirre; Allan R Brasier; Alexander Kurosky; Istvan Boldogh; Sanjiv Sur
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

5.  Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.

Authors:  Paul M O'Byrne; Hristo Metev; Margareta Puu; Kai Richter; Christina Keen; Mohib Uddin; Bengt Larsson; Marie Cullberg; Parameswaran Nair
Journal:  Lancet Respir Med       Date:  2016-08-27       Impact factor: 30.700

6.  Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation.

Authors:  Michiko K Oyoshi; Rui He; Yitang Li; Subhanjan Mondal; Juhan Yoon; Roshi Afshar; Mei Chen; David M Lee; Hongbo R Luo; Andrew D Luster; John S Cho; Lloyd S Miller; Allison Larson; George F Murphy; Raif S Geha
Journal:  Immunity       Date:  2012-10-11       Impact factor: 31.745

7.  Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa?

Authors:  S Sur; T B Crotty; G M Kephart; B A Hyma; T V Colby; C E Reed; L W Hunt; G J Gleich
Journal:  Am Rev Respir Dis       Date:  1993-09

8.  Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease.

Authors:  Dominik Hartl; Philipp Latzin; Peter Hordijk; Veronica Marcos; Carsten Rudolph; Markus Woischnik; Susanne Krauss-Etschmann; Barbara Koller; Dietrich Reinhardt; Adelbert A Roscher; Dirk Roos; Matthias Griese
Journal:  Nat Med       Date:  2007-12-02       Impact factor: 53.440

9.  Neutrophils are required for both the sensitization and elicitation phase of contact hypersensitivity.

Authors:  Felix C Weber; Tamás Németh; Janka Z Csepregi; Anne Dudeck; Axel Roers; Béla Ozsvári; Eva Oswald; László G Puskás; Thilo Jakob; Attila Mócsai; Stefan F Martin
Journal:  J Exp Med       Date:  2014-12-15       Impact factor: 14.307

10.  CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival.

Authors:  Muthulekha Swamydas; Ji-Liang Gao; Timothy J Break; Melissa D Johnson; Martin Jaeger; Carlos A Rodriguez; Jean K Lim; Nathaniel M Green; Amanda L Collar; Brett G Fischer; Chyi-Chia Richard Lee; John R Perfect; Barbara D Alexander; Bart-Jan Kullberg; Mihai G Netea; Philip M Murphy; Michail S Lionakis
Journal:  Sci Transl Med       Date:  2016-01-20       Impact factor: 17.956
  10 in total
  4 in total

1.  The role of CXCR2 in acute inflammatory responses and its antagonists as anti-inflammatory therapeutics.

Authors:  Xiaoyu Zhang; Rongxia Guo; Hiroto Kambara; Fengxia Ma; Hongbo R Luo
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

2.  A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia.

Authors:  Giovanni Landoni; Lorenzo Piemonti; Antonella d'Arminio Monforte; Paolo Grossi; Alberto Zangrillo; Enrico Bucci; Marcello Allegretti; Giovanni Goisis; Elizabeth M Gavioli; Neal Patel; Maria De Pizzol; Georgea Pasedis; Flavio Mantelli
Journal:  Infect Dis Ther       Date:  2022-05-26

3.  Characterization of the Anti-Inflammatory Capacity of IL-10-Producing Neutrophils in Response to Streptococcus pneumoniae Infection.

Authors:  Liliana A González; Felipe Melo-González; Valentina P Sebastián; Omar P Vallejos; Loreani P Noguera; Isidora D Suazo; Bárbara M Schultz; Andrés H Manosalva; Hernán F Peñaloza; Jorge A Soto; Dane Parker; Claudia A Riedel; Pablo A González; Alexis M Kalergis; Susan M Bueno
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 8.786

4.  Therapeutic blockade of CXCR2 rapidly clears inflammation in arthritis and atopic dermatitis models: demonstration with surrogate and humanized antibodies.

Authors:  Md Jahangir Alam; Liang Xie; Caroline Ang; Farnaz Fahimi; Stephen B Willingham; Andrew J Kueh; Marco J Herold; Charles R Mackay; Remy Robert
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.